We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Intestinal Microbiota Determines the Risk of MDRO Acquisition

By LabMedica International staff writers
Posted on 10 Feb 2022
Print article
Image: The Quantus Fluorometer is a compact, dual-channel fluorometer designed to provide highly sensitive fluorescent detection when quantifying nucleic acids (Photo courtesy of Promega)
Image: The Quantus Fluorometer is a compact, dual-channel fluorometer designed to provide highly sensitive fluorescent detection when quantifying nucleic acids (Photo courtesy of Promega)

Colonization and infection by multidrug-resistant organisms (MDRO) remains a public health problem. This is particularly important in intensive care units (ICUs) where the risk of MDRO acquisition/colonization results from the selective pressure associated with prolonged broad-spectrum antibiotic treatment.

Control initiatives consist in detecting patients at high risk of MDRO acquisition, implementation of antibiotic stewardship programs, epidemiological surveillance to detect MDRO intestinal carriage, microbiological tests to rapidly identify MDRO and use of effective measures to reduce their nosocomial transmission.

Clinical Microbiologists at the Hospital Clínic de Barcelona (Barcelona, Spain) conducted a prospective study including patients admitted to a 12-bed ICU between July-December 2018. Rectal swabs to detect MDRO intestinal colonization were obtained at ICU admission and weekly thereafter during ICU-stay. Patients were classified into three groups according to MDRO colonization status. Control group included patients who were not colonized by MDROs at ICU admission and did not get colonized during ICU stay.

The team extracted DNA using the PureLink Microbiome DNA Purification kit (Invitrogen, Carlsbad, MA, USA) and quantified using Quantus Flurometer (Promega, Madison, WI, USA). The 16S rRNA gene sequencing was performed on 138 rectal swabs from 62 patients using the sequenced using Illumina MiSeq platform (Illumina, San Diego, CA, USA). After sequence filtering and sample rarefaction alpha and beta diversity indices were obtained using QIIME2 and statistical analyses were performed.

The investigators reported that of the patients studied, 19/62 (30.65%) presented MDRO colonization at admission, 16/62 (25.81%) were colonized during stay and 27/62 (43.55%) were not colonized; 45/62 (72.58%) developed an infection and mortality was 29.03%. Higher bacterial diversity and abundance of Bacillales Family XI incertae sedis and Prevotella families were associated with lower risk of colonization by MDRO, infection and death while Enterococcaceae family was associated with increased risk of infection and death. The lasso regression and the multivariate analysis identified Family XI incertae sedis to be associated with lower risk of infection (OR=0.997) and microbial evenness index to be associated with lower mortality (OR=0.68) risk.

The authors concluded that microbial diversity and abundance of certain bacterial taxa could have prognostic value in patients admitted to a critical care unit. Larger perspective studies should address the value of these markers in clinical practice. The study was published on January 19, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Hospital Clínic de Barcelona 
Invitrogen 
Promega
Illumina 

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
New
3-Part Diff Hematology Analyzer
DLB3
New
Electrolyte Analyzer
CARELYTE A-Series
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.